» Articles » PMID: 2423028

High-pressure Liquid Chromatographic Methods for Determining Arabinosyladenine-5'-monophosphate, Arabinosyladenine, and Arabinosylhypoxanthine in Plasma and Urine

Overview
Specialty Pharmacology
Date 1985 Aug 1
PMID 2423028
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

New high-pressure liquid chromatographic methods for determining concentrations of arabinosyladenine (Ara-A), its 5'-monophosphate (Ara-AMP), and arabinosylhypoxanthine (Ara-H) in plasma and urine are presented. A fluorescence detector is used for Ara-A and Ara-AMP, which are first converted to highly fluorescent derivatives with chloroacetaldehyde. This increases sensitivity greatly over previous methods. The sensitivities of the methods (in micrograms per milliliter) are as follows: in plasma, Ara-AMP, 0.002; Ara-A, 0.0015; and Ara-H, 0.35; and in urine, 9 times these values, respectively. Drug concentration data are also presented, which were obtained after doses of Ara-AMP were given intramuscularly to two patients treated with this drug for severe herpes zoster. One patient was given 13 mg of Ara-AMP per kg of body weight once daily, and the other was given 6.5 mg/kg twice daily. Peak Ara-AMP and Ara-A levels in plasma occurred within 1 h after the doses, and neither exceeded 2 micrograms/ml. Ara-AMP and Ara-A concentrations in plasma fell to less than 0.01 micrograms/ml in both patients by 4 to 6 h after the doses. Peak Ara-H concentrations in plasma occurred within 1 to 2 h after doses and were 21 micrograms/ml in patient 1 and 2. The highest concentration of Ara-AMP in urine was 0.09 micrograms/ml. The highest Ara-A concentration in urine was 62 micrograms/ml, and the highest Ara-H concentration in urine was 1,080 micrograms/ml. An interfering substance of unknown nature, cochromatographing with Ara-H, was encountered sporadically in urine samples. An algorithm based on differential spectrophotometry to identify and correct for this problem is described. Estimates of the renal clearances of Ara-AMP, Ara-A, and Ara-H are also given.

Citing Articles

Isolation and partial characterization of a new ribosome-inactivating protein from Petrocoptis glaucifolia (Lag.) Boiss.

Arias F, Rojo M, Ferreras J, Iglesias R, Munoz R, Rocher A Planta. 2013; 186(4):532-40.

PMID: 24186783 DOI: 10.1007/BF00198033.


Type 1 ribosome-inactivating proteins are the most abundant proteins in iris (Iris hollandica var. Professor Blaauw) bulbs: characterization and molecular cloning.

Van Damme E, Barre A, Barbieri L, Valbonesi P, Rouge P, Van Leuven F Biochem J. 1997; 324 ( Pt 3):963-70.

PMID: 9210423 PMC: 1218515. DOI: 10.1042/bj3240963.


Polynucleotide: adenosine glycosidase activity of saporin-L1: effect on DNA, RNA and poly(A).

Barbieri L, Valbonesi P, Gorini P, Pession A, Stirpe F Biochem J. 1996; 319 ( Pt 2):507-13.

PMID: 8912688 PMC: 1217797. DOI: 10.1042/bj3190507.


Effects of ribosome-inactivating proteins on Escherichia coli and Agrobacterium tumefaciens translation systems.

Girbes T, Barbieri L, Ferreras M, Arias F, Rojo M, Iglesias R J Bacteriol. 1993; 175(20):6721-4.

PMID: 8407849 PMC: 206786. DOI: 10.1128/jb.175.20.6721-6724.1993.


High-pressure-liquid-chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin.

Zamboni M, Brigotti M, Rambelli F, Montanaro L, Sperti S Biochem J. 1989; 259(3):639-43.

PMID: 2730579 PMC: 1138566. DOI: 10.1042/bj2590639.


References
1.
Roos H, Pfleger K . Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole. Mol Pharmacol. 1972; 8(4):417-25. View

2.
Hare R . Endogenous creatinine in serum and urine. Proc Soc Exp Biol Med. 1950; 74(1):148-51. DOI: 10.3181/00379727-74-17837. View

3.
Bryson Y, Sweetman L, Connor J . Simple sensitive microbioassay for adenine arabinoside and hypoxanthine arabinoside in human plasma. Antimicrob Agents Chemother. 1978; 14(6):909-15. PMC: 352578. DOI: 10.1128/AAC.14.6.909. View

4.
Buchanan R, Kinkel A, Alford Jr C, Whitley R . Plasma levels and urinary excretion of vidarabine after repeated dosing. Clin Pharmacol Ther. 1980; 27(5):690-6. DOI: 10.1038/clpt.1980.98. View

5.
Aronoff G, Szwed J, Nelson R, Marcus E, Kleit S . Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Antimicrob Agents Chemother. 1980; 18(1):212-4. PMC: 283968. DOI: 10.1128/AAC.18.1.212. View